Top News

August 2018

  • GRAF_Featured

    Microbiology’s shifting role in war on sepsis

    August 2018—If you were casting about for the severest test of a laboratory’s capabilities, day in and day out, sepsis admissions at a pediatric hospital might fit the bill. At Children’s Hospital of Philadelphia, and at other hospitals, waging war on sepsis requires battles on multiple fronts and clinical pathways that rely on an agile and highly equipped microbiology laboratory. Three main categories of patients ensure there is no shortage of sepsis cases at CHOP, says Erin H. Graf, PhD, D(ABMM), director of the infectious disease diagnostics laboratory. “We’re a very large oncology center with a lot of children with hematologic malignancies as patients, who are certainly at high risk for sepsis.”

    Read More »
  • Dr. Hernandez

    Addressing the gender gap: Women and burnout—like men, but not

    August 2018—Jennifer Hunt, MD, gave it her best shot. While picking up her son after school one day (a task she only rarely had time for) and hearing staff ask, “Who are you?” yet again, followed by, “Oh, you’re Joel’s mom—we didn’t think you existed” …

  • ‘We found that NT-proBNP concentration of 400 pg/mL as the point between so-called high and low NT-proBNP worked very well.’
—Petr Jarolim, MD, PhD

    Serial NT-proBNP found to identify risk for adverse CV outcomes

    August 2018—For diabetes type 2 patients with cardiovascular disease, findings of a new study support clinicians’ use of serial measures of NT-proBNP concentrations to make critical treatment decisions easier by basing them on risk of major cardiovascular events, including heart failure.

  • Weck_Karen

    PGx testing: recommended alleles for CYP2C19 panels

    August 2018—After more than a year of gathering information and deliberating, members of the Association for Molecular Pathology Pharmacogenomics Working Group have issued the first in what will be a series of recommendations to standardize pharmacogenetic testing.

Image Credits: lorem ipsum, Procust, Month issue, etc..

AUGUST DEPARTMENTS

  • Put It on the Board

    Cobas HPV test approved for first-line screening using SurePath preservative fluid
    August 2018—Roche received FDA approval for the Cobas HPV test to be used as the first-line screening test for cervical cancer in women 25 and older using specimens collected in SurePath preservative fluid. The Roche test is now the only HPV test approved for use as a primary screening test with both SurePath and ThinPrep PreservCyt Solution. It is approved for all of the screening indications supported by guidelines—primary screening in women 25 and older, reflex testing of unclear Pap test results in women 21 and older, and cotesting with a Pap test in women 30 and older—with both of the primary collection media types. “With this additional approval for the Cobas HPV Test, laboratories and clinicians now have an approved option that can be used for all of their HPV screening indications and sample types,” Ann Costello, head of Roche tissue diagnostics, said in a statement.

    Read More »
  • Clinical pathology selected abstracts

    Association of perioperative RBC transfusions with venous thromboembolism
    August 2018—Hospital-associated venous thromboembolism is a major cause of morbidity and mortality, resulting in 100,000 to 200,000 deaths annually. Surgery can lead to a proinflammatory state and be a prothrombotic stimulus for venous thromboembolism (VTE).

  • Q&A column

    August 2018—I would like to start fecal fat testing in my laboratory, using the Sudan black staining method. What is the best way to report fecal fat testing? Who developed the formula for the corrected white blood cell count for nucleated red blood cells, and how was the formula established?

  • Click to view these CAP TODAY departments:
    President’s Desk
    Clinical pathology selected abstracts
    Anatomic pathology selected abstracts
    Molecular pathology selected abstracts
    Q&A column
    Newsbytes
    Put It on the Board
    Marketplace

Image Credits: lorem ipsum, Procust, Month issue, etc..

CAP TODAY Recommends

  • Cancer Biomarkers Conference III

    Houston Methodist Department of Pathology and Genomic Medicine is presenting its Cancer Biomarkers Conference III, Sept. 15–16, at the Houston Methodist Research Institute. More than 20 speakers will cover topics such as updates on PD-L1 testing for lung cancer, urologic cancers, and melanoma, the current approach to using cytology specimens for biomarker testing, the oncologist’s approach to TKI therapy, and many more. The conference’s educational objectives include distinguishing the proper collection, management, and submission of pathology specimens for cancer …

    Read More »
  • CMS national coverage decision on next-generation sequencing

    A new white paper titled “The CMS National Coverage Decision on NGS” from Diaceutics provides coverage of ongoing developments since the NGS national coverage decision was made. Read the white paper (requires free registration).

  • VIDEO SERIES: The future of the lab in health care

    In a collaborative effort to discuss the future of the laboratory in health care, Bob McGonnagle, publisher of CAP TODAY, gathered with Orchard Software’s Curt Johnson, chief operating officer, and Matt Modleski, chief operating officer, American Health Network. This roundtable was edited into a series of seven short videos.

Image Credits: lorem ipsum, Procust, Month issue, etc..

Cytopathology

  • Milan_FeaturedImage2

    Cytopathology in Focus: Reporting salivary gland cytopathology—new user-friendly Milan system consists of six diagnostic categories

    May 2018—The Milan System for Reporting Salivary Gland Cytopathology was published Jan. 31 and is an important step toward standardizing the reporting of salivary gland fine needle aspiration. A large body of literature has demonstrated that FNA is an effective method for the initial evaluation of salivary gland masses, but until this year there was no uniform, widely accepted reporting system. The complexity of salivary gland cytology poses unique challenges that demand a standardized approach to communication of diagnostic information between pathologists and treating clinicians.

    Read More »
  • Cytopathology in Focus: For thyroid cytopathology, the 2017 Bethesda System

    May 2018—Surgical pathologists take their tumor nomenclature from the WHO Classification of Tumours, but cytopathologists take their terminology from where the consensus groups convened—Bethesda, Paris, Milan, and Yokohama—to formulate terminology recommendations. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC)1 is now in its second edition.

  • Modified Giemsa stain. Highly cellular smear showing fibroadenoma with mix of small and large hyperplastic ductal epithelial cell tissue fragments and large myxoid stromal fragments. High-power image shows myoepithelial nuclei on the epithelial fragments and in the background as bare bipolar nuclei. Inset: Modified Giemsa. Fragment of benign breast tissue consisting of ductal epithelial cells with interspersed myoepithelial cells.

    Cytopathology in Focus: Standardized reporting for breast FNAB cytology

    January 2018—In countries with developed medical infrastructure, the use of breast fine-needle aspiration biopsy (FNAB) cytology has had its share of challenges over the past 20 years, among them the use of core needle biopsies. In developing countries where the use of FNAB cytology has been increasing rapidly, breast lesions are one of the most common sites sampled by FNAB. In 2016, the International Academy of Cytology Executive Council put together a “Breast Group,” which consists of cytopathologists, surgical pathologists, radiologists, surgeons, and oncologists working in breast care, with the aim of producing a comprehensive and standardized approach to breast FNAB cytology reporting.

Image Credits: lorem ipsum, Procust, Month issue, etc..

MARKETPLACE

  • Disease state sera, plasma products

    August 2018—Binding Site’s Immunologicals Group has added infectious and contagious disease state sera and plasma products to its line of products. The human-based serum/plasma biological materials cover a variety of infectious and contagious disease state conditions, including Epstein-Barr virus, influenza, measles, mumps, TORCH, and West Nile. Evaluation samples are available and all materials come in bulk formats for use in the manufacturing of calibration and quality control materials. The company offers comprehensive data on analyte positives and negatives along with a certificate of analysis.

    Read More »
  • 539-AquaroHistology

    Aquaro Wishbone blade-handling tool

    August 2018—Aquaro Histology announced the launch of the Aquaro Wishbone blade-handling tool. The handheld tool allows histologists to remove and dispose of blades, as well as insert and align them, without having to touch the blade.

  • Natera, Institut Jules Bordet collaborate

    August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.

Image Credits: lorem ipsum, Procust, Month issue, etc..

X